Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended September 30, 2026

October 09, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block, Bandra Kurla Complex, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Intimation of Board Meeting Ref: Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the meeting of the Board of Directors of Aarti Pharmalabs Limited is scheduled to be held on Wednesday, October 28, 2026, inter alia, to consider and approve the Unaudited Financial Results (standalone and consolidated) for the quarter and half year ended September 30, 2026 along with the Limited Review Reports of the Auditors for the corresponding period. Further, in terms of Code for Prevention of Insider Trading in the Securities of the Company, the Trading Window for transactions in the securities of the Company which was closed from October 01, 2026, shall remain closed until October 30, 2026 for the purpose of announcement of aforesaid results. Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565